# Clinical Trials Data KIT - Document 41

# Autologous Versus Synthetic Versus Biological Sling for Trans-obturator Correction of Urinary Stress Incontinence

## Clinical Trial: https://clinicaltrials.gov/study/NCT00744198

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Genuine stress urinary incontinence by self report, examination and test\n\* Urethral hypermobility\n\* Eligible for all three surgical procedures\n\* Ambulatory\n\nExclusion Criteria:\n\n\* Pregnancy\n\* \\<12 months post-partum\n\* Systemic disease and/or drugs known to affect bladder function\n\* Current chemotherapy or radiation therapy\n\* Urethral diverticulum, augmentation cytoplasty, or artificial sphincter\n\* Recent pelvic surgery\n\* Severe genuine stress incontinence (loss of urine with minimal physical activity) with associated prolapse equal to or more than second degree\n\* Previous pelvic or anti-incontinence surgery\n\* History of severe abdominopelvic infections\n\* Known extensive abdominopelvic adhesions\n\* Detrusor instability and/or intrinsic sphincter dysfunction\n\* Other gynaecologic pathologies (eg, fibroids, ovarian cysts)\n\* BMI \\>30",  
 "healthyVolunteers": false,  
 "sex": "FEMALE",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
The clinical trial information you provided focuses on criteria related to stress urinary incontinence and various conditions affecting the pelvic area, as well as specific health and surgical history parameters. However, it does not mention anything about specific genetic mutations, including a KIT gene mutation, as part of the inclusion or exclusion criteria.   
  
Given this information, having a KIT gene mutation alone would not automatically make a patient ineligible, as it is not listed in the selection criteria. The determining factor would focus on whether the patient meets or does not meet the other criteria outlined in the trial. It's important for the patient to consult with a healthcare provider or the administrators of the trial for more specific guidance.